Page 356 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

330 Vanessa Quick and John Kirwan

[81] Parikh M, Miller NR, Lee AD, et al. Prevalence of a normal C-reactive protein with an
elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis.
Ophthalmology, 2006; 113:1842–1845.

[82] Salvarani C, Hunder GG. Giant Cell Arteritis with Low Erythrocyte Sedimentation
Rate: Frequency of Occurrence in a Population-Based Study. Arthritis Care Res., 2001;
45:140–145.

[83] Walvick MD, Walvick MP. Giant cell arteritis: laboratory predictors of a positive
temporal artery biopsy. Ophthalmology, 2011; 118:1201-1204.

[84] Kermani TA, Schmidt J, Cynthia S, et al. Utility of erythrocyte sedimentation rate and
C-reactive protein for the diagnosis of giant cell arteritis. Semin. Arthritis Rheum.,
2012; 41:866-871.

[85] Pountain G, Hazleman B. Polymyalgia Rheumatica and Giant Cell Arteritis. BMJ,
1995; 310:1057-1059.

[86] Pipitone N, Salvarani C. Improving therapeutic options for patients with giant cell
arteritis. Curr Opin. Rheumatol., 2008; 20:17-22.

[87] Narváez J, Bernad B, Roig-Vilaseca D, et al. Influence of previous corticosteroid
therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum.,
2007; 37:13-19.

[88] Danesh-Meyer HV. Temporal artery biopsy: skip it at your patient?s peril. Am. J.
Ophthalmol., 2012; 154:617-619.

[89] Drehmer TJ, Khanna D, Markert RJ, et al. Diagnostic and management trends of giant
cell arteritis: A physician survey. J. Rheumatol., 2005; 32:1283-1289.

[90] Delecoeullerie D, Joly P, Cohen de Lara A. et al. Polymyalgia rheumatica and temporal
arteritis: a retrospective analysis of prognostic features and different corticosteroid
regimens (11 year survey of 210 patients). Ann. Rheum. Dis., 1988; 9:733-739.

[91] Varma D, O?Neill D. Quantification of the role of temporal artery biopsy in diagnosing
clinically suspected giant cell arteritis. Eye, 2004; 18:384-388.

[92] Thomassen I, den Brok AN, Konings CJ, et al. Steroid use is associated with clinically
irrelevant biopsies in patients with suspected giant cell arteritis. The American Surgeon,
2012; 78):1362-1368.

[93] Niederkohr RD, Levin LA. A Bayesian analysis of the true sensitivity of a temporal
artery biopsy. Invest. Ophthalmol. Vis. Sci., 2007; 48:675–680.

[94] Sudlow C. Diagnosing and managing polymyalgia rheumatica and temporal arteritis.
Sensitivity of temporal artery biopsy varies with biopsy length and sectioning strategy.
BMJ, 1997; 315:549.

[95] Taylor-Gjevre R, Vo M, Shukla D, et al. Temporal artery biopsy for giant cell arteritis.
J. Rheum., 2005; 32:1279-1282.

[96] Ypsilantis E, Courtney ED, Chopra N, et al. Importance of specimen length during
temporal artery biopsy. Br. J. Surg., 2011; 98:1556-1560.

[97] Goslin BJ, Chung MH. Temporal artery biopsy as a means of diagnosing giant cell
arteritis: is there over-utilization? Am. Surg., 2011; 77:1158-1160.

[98] Lie T et al. Illustrated criteria for histopathologic classification of selected vasculitis
syndromes. Arthritis Rheum., 1990; 33:1074-1087.

[99] Murchison AP, Bilyk JR, Eagle RC, et al. Shrinkage revisited: how long is long
enough? Ophthalmic Plastic and Reconstructive Surgery, 2012; 28:261-263.

Complimentary Contributor Copy